论文部分内容阅读
目的评价经皮腔内冠脉介入治疗(PCI)中运用国产雷帕霉素洗脱支架(乐普PARTNER)治疗进展期ST段抬高型心肌梗死患者的安全性和临床疗效。方法2006年8月—2007年11月对65例进展期ST段抬高型心肌梗死患者运用乐普PARTNER行急诊PCI血运重建,术后对患者进行随访,观察有无胸痛复发、心电图异常改变、严重心血管不良事件等。结果65例患者共植入乐普PARTNER 101枚。术中63例患者于“罪犯血管”(IRA)处急诊植入乐普PARTNER支架,即刻成功率96.9%(63/65),恢复TIMIⅢ级血流92.3%(60/65),住院期间及随访6个月无胸痛症状发作,无心电图异常改变,无严重心血管不良事件发生。结论乐普PARTNER治疗进展期ST段抬高型心肌梗死即刻成功率高,并发症少,近期安全性和临床疗效确切。
Objective To evaluate the safety and clinical efficacy of domestic rapamycin-eluting stent (LEP PARTNER) in patients with advanced ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary intervention (PCI). METHODS: From August 2006 to November 2007, 65 patients with advanced ST-segment elevation myocardial infarction were enrolled in this study. LEP PARTNER was used for emergency revascularization of PCI. Postoperative follow-up was performed on patients with or without recurrent chest pain and abnormal electrocardiogram , Serious adverse cardiovascular events. Results A total of 101 PLUS PARTNERs were implanted in 65 patients. Sixty-three patients were enrolled in the LEPP PARTNER stent immediately at the “IRA” site. The immediate success rate was 96.9% (63/65), and the TIMI III grade blood flow was restored to 92.3% (60/65). During the hospitalization period, And no follow-up of 6 months without chest pain symptoms, no abnormal ECG changes, no serious adverse cardiovascular events. Conclusion LEP PARTNER treatment of advanced ST elevation myocardial infarction immediately high success rate, fewer complications, the recent safety and clinical efficacy of the exact.